Literature DB >> 22951236

The epidemiology of depression and the evolution of treatment.

Robert M A Hirschfeld1.   

Abstract

Depression is a prevalent and pernicious disorder. About 1 in 5 US adults have at least 1 lifetime episode of major depression. Of those with depression, the majority will relapse over the long-term and many will have poor mental health outcomes and psychosocial disabilities. Over the past century, a range of treatments, including medications with varying mechanisms of action, have been developed to manage depression. Treatments from seizure therapies to an array of medications--amphetamine, tricyclic antidepressants, monoamine oxidase inhibitors, mixed-action antidepressants, selective serotonin reuptake inhibitors, and dual reuptake inhibitors--have evolved. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951236     DOI: 10.4088/JCP.11096su1c.01

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  28 in total

1.  Effects of Jiaotaiwan on depressive-like behavior in mice after lipopolysaccharide administration.

Authors:  Qian Zhe; Wang Sulei; Tao Weiwei; Long Hongyan; Wang Jianwei
Journal:  Metab Brain Dis       Date:  2016-10-30       Impact factor: 3.584

2.  Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.

Authors:  Leslie R Amodeo; Venuz Y Greenfield; Danielle E Humphrey; Veronica Varela; Joseph A Pipkin; Shannon E Eaton; Jelesa D Johnson; Christopher P Plant; Zachary R Harmony; Li Wang; Cynthia A Crawford
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

Review 3.  The neuroscience of depression: implications for assessment and intervention.

Authors:  Manpreet K Singh; Ian H Gotlib
Journal:  Behav Res Ther       Date:  2014-09-04

4.  A pilot integrative genomics study of GABA and glutamate neurotransmitter systems in suicide, suicidal behavior, and major depressive disorder.

Authors:  Honglei Yin; Spiro P Pantazatos; Hanga Galfalvy; Yung-Yu Huang; Gorazd B Rosoklija; Andrew J Dwork; Ainsley Burke; Victoria Arango; Maria A Oquendo; John J Mann
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-02-19       Impact factor: 3.568

Review 5.  Exercise training and depression and anxiety in musculoskeletal pain patients: a meta-analysis of randomized control trials.

Authors:  Sohrab Amiri
Journal:  Neuropsychiatr       Date:  2022-09-20

6.  The Impact of Chronic Unpredictable Mild Stress-Induced Depression on Spatial, Recognition and Reference Memory Tasks in Mice: Behavioral and Histological Study.

Authors:  Ghofran Khalid Alqurashi; Emad A Hindi; Mohamed A Zayed; Gamal S Abd El-Aziz; Hani A Alturkistani; Rabee F Ibrahim; Mona Ali Al-Thepyani; Refal Bakhlgi; Noor A Alzahrani; Ghulam Md Ashraf; Badrah S Alghamdi
Journal:  Behav Sci (Basel)       Date:  2022-05-29

Review 7.  Vilazodone: a review in major depressive disorder in adults.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

8.  Prevalence of clinical anxiety, clinical depression and associated risk factors in chinese young and middle-aged patients with osteonecrosis of the femoral head.

Authors:  Sheng-Bao Chen; Hai Hu; You-Shui Gao; Hai-Yan He; Dong-Xu Jin; Chang-Qing Zhang
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

9.  The Prevalence and Correlative Factors of Depression Among Chinese Teachers During the COVID-19 Outbreak.

Authors:  Jiaojiao Zhou; Xiaofei Yuan; Huanhuan Huang; Yaqiong Li; HongYe Yu; Xu Chen; Jia Luo
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

10.  Ketamine as antidepressant? Current state and future perspectives.

Authors:  H W W Hasselmann
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.